Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

被引：114

作者：

Rixe, Olivier ^{[1
]}

Fojo, Tito ^{[2
]}

机构：

[1] Univ Paris 06, Salpetriere Hosp, Dept Med Oncol, Paris, France

[2] Natl Canc Inst, Med Oncol Branch, Canc Res Ctr, Bethesda, MD USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 24期

关键词：

D O I：

10.1158/1078-0432.CCR-07-2141

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since the discovery of conventional chemotherapy and the development of new target-based agents, the importance of cytostasis in anticancer activity has been debated. This review examines the relative importance of both cytostasis and cytotoxicity based on both preclinical data and clinical reports. Several limitations of our basic and clinical methods to evaluate cytostasis and cytotoxicity will be highlighted. Molecular mechanisms of cytostasis will be analyzed, including interference with the cell cycle as well as putative links with necrosis and autophagy. Finally, we will cite evidence that most older and newer compounds are both cytostatic and cytotoxic. The relative role of cytostasis and cytotoxicity on future drug screening and clinical development will be explored.

引用

页码：7280 / 7287

页数：8

共 59 条

[1] Epothilones: A novel class of non-taxane microtubule-stabilizing agents [J].

Altaha, R ;

Fojo, T ;

Reed, E ;

Abraham, J .

CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (19) :1707-1712

[2] The roles of therapy-induced autophagy and necrosis in cancer treatment [J].

Amaravadi, Ravi K. ;

Thompson, Craig B. .

CLINICAL CANCER RESEARCH, 2007, 13 (24) :7271-7279

[3]

AMATO RJ, 2007, P AM SCO CLIN ONCOL, V25, P5026

[4] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].

Banerji, U ;

O'Donnell, A ;

Scurr, M ;

Pacey, S ;

Stapleton, S ;

Asad, Y ;

Simmons, L ;

Maloney, A ;

Raynaud, F ;

Campbell, M ;

Walton, M ;

Lakhani, S ;

Kaye, S ;

Workman, P ;

Judson, I .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161

[5] Targeting the cell death-survival equation [J].

Benz, Edward J., Jr. ;

Nathan, David G. ;

Amaravadi, Ravi K. ;

Danial, Nika N. .

CLINICAL CANCER RESEARCH, 2007, 13 (24) :7250-7253

[6]

Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO

[7]

2-5

[8] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[9] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].

Byrd, John C. ;

Lin, Thomas S. ;

Dalton, James T. ;

Wu, Di ;

Phelps, Mitch A. ;

Fischer, Beth ;

Moran, Mollie ;

Blum, Kristie A. ;

Rovin, Brad ;

Brooker-McEldowney, Michelle ;

Broering, Sarah ;

Schaaf, Larry J. ;

Johnson, Amy J. ;

Lucas, David M. ;

Heerema, Nyla A. ;

Lozanski, Gerard ;

Young, Donn C. ;

Suarez, Jose-Ramon ;

Colevas, A. Dimitrios ;

Grever, Michael R. .

BLOOD, 2007, 109 (02) :399-404

[10] Biochemical Mechanisms of Cisplatin Cytotoxicity [J].

Cepeda, Victoria ;

Fuertes, Miguel A. ;

Castilla, Josefina ;

Alonso, Carlos ;

Quevedo, Celia ;

Perez, Jose M. .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (01) :3-18

← 1 2 3 4 5 6 →